Keywords
How to Cite
Abstract
Abstract: This article analyzes the clinical features, biological basis, and treatment strategies of 24 patients with resistant depression (RD). The results of the study show that long-term angedonia, psychomotor inhibition, sleep, and cognitive impairments are common in RD. Biologically, patients showed high levels of cortisol and low BDNF, while fMRI results confirm dysfunction of the prefrontal cortex and limbic system. Combined pharmacotherapy, ketamine infusions, transcranial magnetic stimulation, and psychotherapy are effective in the treatment. The study demonstrates the importance of treating RD with an individual approach and emphasizes the possibilities of personalized therapy based on biological markers in the future.
References
1. Fava, M., & Davidson, K. G. (2016). Definition and epidemiology of treatment-resistant depression. Psychiatric Clinics of North America, 39(2), 1–17.
2. Rush, A. J., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STARD report*. American Journal of Psychiatry, 163(11), 1905–1917.
3. Malhi, G. S., et al. (2015). Treatment-resistant depression: Pharmacological approaches. Australian & New Zealand Journal of Psychiatry, 49(1), 15–26.
4. Duman, R. S., & Aghajanian, G. K. (2012). Synaptic dysfunction in depression: Potential therapeutic targets. Science, 338(6103), 68–72.
5. McIntyre, R. S., et al. (2020). Novel approaches to treatment-resistant depression: Ketamine, neuromodulation, and precision medicine. CNS Drugs, 34(8), 765–783.
6. Gaynes, B. N., et al. (2014). Defining treatment-resistant depression. Depression and Anxiety, 31(1), 1–10.
7. Carpenter, L. L., et al. (2012). Transcranial magnetic stimulation for treatment-resistant depression: A review. CNS Spectrums, 17(4), 245–252.
8. Sanacora, G., et al. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74(4), 399–405.
9. Nemeroff, C. B., & Vale, W. (2005). The neurobiology of depression: Insights from studies of corticotropin-releasing factor. Trends in Neurosciences, 28(9), 481–487.
10. Murrough, J. W., et al. (2013). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry, 74(4), 250–256.
11. Kessler, R. C., et al. (2003). The epidemiology of major depressive disorder: Results from the National Comorbidity Survey. JAMA, 289(23), 3095–3105.
12. Schlaepfer, T. E., et al. (2014). Deep brain stimulation for treatment-resistant depression: Review of clinical studies. CNS Drugs, 28(6), 467–478.
13. McAllister-Williams, R. H., et al. (2017). Biological markers and personalized treatment in depression. Current Opinion in Psychiatry, 30(1), 10–17.